In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Ipsen

European OTC Results Round-Up: HRA Pharma, Boiron and Ipsen

HRA Pharma reports impressive sales growth in 2018, thanks largely to acquisitions. A drop in demand for homeopathic medicines hurts Boiron in Q1, while Ipsen enjoys a solid start to the year. 
Sales & Earnings OTC Drugs

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Deals Business Strategies

Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year

Sanofi tells investors to expect further Consumer Healthcare brand divestments in 2019 as it continues to rationalize its portfolio following the transformational acquisition of Boehringer Ingelheim's OTC business in 2017. As a result of divestments in 2018, as well as a number of seasonal factors, Sanofi reported a 0.6% rise in Consumer Healthcare's sales in Q1.
Business Strategies Sales & Earnings

'Pharma Fireworks': Pipeline Catalysts To Watch Out For In Q2

Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.

Clinical Trials Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Beaufour Ipsen
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • David Meek, CEO
    Aymeric Le Chatelier, EVP, Fin. & CFO
    Alexandre Lebeaut, MD, EVP, R&D & CSO
    Ivana Magovcevic-Liebisch, EVP, CBO
  • Contact Info
  • Ipsen
    Phone: (33) 1 58 33 50 00
    65 Quai George Gorse
    Boulogne-Billancourt, 92100
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register